Adult infected w/ HIV-1 w/o documented or clinically suspected resistance to the integrase class 50 mg once daily. In combination w/ efavirenz, nevirapine, tipranavir/ritonavir or rifampicin: 50 mg bid. Adult infected w/ HIV-1 w/ resistance to the integrase class 50 mg bid. Adolescents ≥12 yr at least 40 kg infected w/ HIV-1 w/o resistance to the integrase class 50 mg once daily.
Hypersensitivity reactions. Activity is considerably compromised for viral strains harbouring Q148+≥2 secondary mutations from G140A/C/S, E138A/K/T, L74I in the presence of integrase class resistance. Monitor liver biochemistries in patients w/ hepatitis B &/or C co-infection. Immune reactivation syndrome. Opportunistic infections. Concomitant use w/ drugs that reduce dolutegravir exposure [eg, Mg- or Al-containing antacid, Fe & Ca supplements, multivit & inducing agents, etravirine (w/o boosted PIs), tipranavir/ritonavir, rifampicin, St. John's wort & antiepileptics]. Monitor renal function in patients co-treated w/ metformin; may increase risk for lactic acidosis in patients w/ moderate renal impairment. Osteonecrosis in patients w/ advanced HIV-disease &/or long-term exposure to CART. Pregnancy & lactation.
Sign Out
